Protara Therapeutics, Inc.TARA
Price (close)
$3.35
Market cap
$198.0M
P/E
—
Revenue (TTM)
—
Net income
-$70.0M
Dividend yield
—
1-year total return
-21.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What Protara Therapeutics, Inc. does.
clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases.
We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in
order to create new development opportunities. We prioritize creativity, integrity and tenacity to expedite our goal of bringing life-changing
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
| Free cash flow | -$24.3M | -$35.1M | -$26.6M | -$37.6M | -$35.9M | -$56.5M |
More on TARA.
- Protara Therapeutics, Inc. summary
- Protara Therapeutics, Inc. financial statements
- Protara Therapeutics, Inc. key metrics
- Protara Therapeutics, Inc. health scores and style box
- Protara Therapeutics, Inc. earnings
- Protara Therapeutics, Inc. dividends
- Protara Therapeutics, Inc. valuation
- Protara Therapeutics, Inc. ownership and insiders
- Protara Therapeutics, Inc. peers
Figures from Protara Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.